Vivacta Biotechnology
Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases
$50MSeries A+
Role not disclosedQV
Qiming Venture Partners
Activity from announced rounds
Activity in this selectionHealthtech
- Rounds participated in
- 6
- Confirmed lead rounds
- — 6 roles undisclosed
- New companies
- 5 First participation on record · 1 follow-on
- Funding in participating rounds
- $536.5M 6 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
6 in this selectionPulnovo Medical
Develops interventional therapies for pulmonary hypertension and heart failure
$100MStrategic
Role not disclosedVivatides Therapeutics
Develops extrahepatic RNA-targeting therapeutics
$54MSeries A
Role not disclosedOricell Therapeutics
Develops next-generation cell therapies for oncology and immunology
$110MPre-IPO
Role not disclosedSyneron Bio
Develops intelligent platform-driven macrocyclic peptide drug discovery
$150MSeries B
Role not disclosedStairMed
Develops minimally invasive implantable brain-machine interfaces (BMI) for neurological diseases
CN¥500MStrategic
Role not disclosed